Search | Clinical Trials Finder

Conditions: Gynecologic Cancer, Carcinoma, Uterine Cancer, Endometrial Cancer
Interventions: Cabo + Dostarlimab; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Neoplasms, Head and Neck
Interventions: Dostarlimab, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 864 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 36
States / cities: Jonesboro, Arkansas • Los Angeles, California • Solvang, California + 33 more

Conditions: Advanced/Metastatic NSCLC
Interventions: Immunotherapy - PD-1 Blocker; Drug
Lead sponsor: Liza Villaruz, MD; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Neoplasms
Interventions: GSK3745417, Dostarlimab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma Stage III, Melanoma Stage IV
Interventions: Dostarlimab (TSR-042) (singly), Dostarlimab (TSR-042) and TSR-022 (combination); Drug
Lead sponsor: Diwakar Davar; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Pittsburgh, Pennsylvania + 1 more

Conditions: Brain Metastases
Interventions: Niraparib, Dostarlimab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neoplasms, Rectal
Interventions: Dostarlimab; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 7
States / cities: Los Angeles, California • Albuquerque, New Mexico • New York, New York + 4 more

Conditions: Recurrent Endometrial Serous Adenocarcinoma
Interventions: Biospecimen Collection, Computed Tomography, Dostarlimab, Magnetic Resonance Imaging, Niraparib; Procedure · Biological · Drug
Lead sponsor: Casey Cosgrove; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm
Interventions: Atezolizumab, Avelumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab, Quality-of-Life Assessment, Short-Term Fasting, Dostarlimab, Retifanlimab, Toripalimab, Tislelizumab; Drug · Biological · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Deleterious PALB2 Gene Mutation
Interventions: Niraparib, Dostarlimab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 8
States / cities: New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Interventions: Niraparib, Dostarlimab (TSR-042), Standard of care, Dostarlimab-Placebo, Niraparib-Placebo; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 65
States / cities: Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 55 more

Conditions: Neoplasms
Interventions: feladilimab (GSK3359609), GSK3174998, Pembrolizumab, Docetaxel, Pemetrexed, Paclitaxel plus Carboplatin, Gemcitabine plus Carboplatin, Fluorouracil (5-FU) plus carboplatin or cisplatin, Dostarlimab, Cobolimab, Bintrafusp alfa; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 93 Years
Enrollment: 829 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 9
States / cities: Duarte, California • Los Angeles, California • Sarasota, Florida + 4 more

Conditions: Neoplasms
Interventions: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 64
States / cities: Goodyear, Arizona • Scottsdale, Arizona • Tucson, Arizona + 56 more

Conditions: Lung Cancer, Non-Small Cell
Interventions: Dostarlimab, Belrestotug, Pembrolizumab, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Ocala, Florida • Honolulu, Hawaii • Lexington, Kentucky + 4 more

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, BRCA-Associated Malignant Neoplasm, BRCA Hereditary Ovarian Carcinoma, Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Primary Peritoneal Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Unresectable Breast Carcinoma, Unresectable Fallopian Tube Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Ovarian Carcinoma, Unresectable Pancreatic Carcinoma, Unresectable Primary Peritoneal Carcinoma
Interventions: Dostarlimab, Niraparib, Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging; Biological · Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Lung Cancer, Non-Small Cell
Interventions: Dostarlimab, Pembrolizumab, Chemotherapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Denver, North Carolina • Cincinnati, Ohio • Fairfax, Virginia

Conditions: Colon Cancer, dMMR Colorectal Cancer
Interventions: Dostarlimab; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: Iowa City, Iowa • Madison, Wisconsin

Conditions: Multiple Myeloma
Interventions: Belantamab mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab, Isatuximab, Lenalidomide, Dexamethasone, Pomalidomide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Indianapolis, Indiana • Boston, Massachusetts + 2 more

Conditions: Endometrial Cancer
Interventions: Paclitaxel, Carboplatin, Dostarlimab, Cisplatin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Endometrial Cancer
Interventions: Intensity modulated radiation therapy (IMRT), Dostarlimab, Hypofractionated IMRT; Radiation · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Neoplasms
Interventions: Dostarlimab, Placebo matching dostarlimab, Carboplatin, Paclitaxel, Niraparib, Placebo matching Niraparib; Biological · Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 785 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 59
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 49 more

Conditions: Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM), Diffuse Intrinsic Pontine Glioma (DIPG), Ependymoma, Osteosarcoma, Hepatic Tumors, Hepatoblastoma, Hepatocellular Carcinoma (HCC), Fibrolamellar Carcinoma, Rhabdomyosarcoma
Interventions: Cobolimab, Dostarlimab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 0 Years to 21 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • Iowa City, Iowa • Hackensack, New Jersey + 3 more

Conditions: Neoplasms, Head and Neck
Interventions: Dostarlimab, Belrestotug, Nelistotug, Remzistotug; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: New Haven, Connecticut • Iowa City, Iowa • St Louis, Missouri + 2 more

Conditions: Ovarian Neoplasm
Interventions: Dostarlimab, Bevacizumab, Niraparib; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 6 more

Search by objective public record fields.

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Impact of Circadian Rhythm on Immunotherapy

A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer